Device-assisted enteroscopy performance measures in the United Kingdom: DEEP-UK quality improvement project

BACKGROUND

Device-assisted enteroscopy (DAE) has become a well-established diagnostic and therapeutic tool for the management of small-bowel pathology. We aimed to evaluate the performance measures for DAE across the UK against the quality benchmarks proposed by the European Society of Gastrointestinal Endoscopy (ESGE).

METHODS

We retrospectively collected data on patient demographics and DAE performance measures from electronic endoscopy records of consecutive patients who underwent DAE for diagnostic and therapeutic purposes across 12 enteroscopy centers in the UK between January 2017 and December 2022.

RESULTS

A total of 2005 DAE procedures were performed in 1663 patients (median age 60 years; 53% men). Almost all procedures (98.1%) were performed for appropriate indications. Double-balloon enteroscopy was used for most procedures (82.0%), followed by single-balloon enteroscopy (17.2%) and spiral enteroscopy (0.7%). The estimated depth of insertion was documented in 73.4% of procedures. The overall diagnostic yield was 70.0%. Therapeutic interventions were performed in 42.6% of procedures, with a success rate of 96.6%. Overall, 78.0% of detected lesions were marked with a tattoo. Patient comfort was significantly better with the use of deep sedation compared with conscious sedation (99.7% vs. 68.5%; P<0.001). Major adverse events occurred in only 0.6% of procedures.

CONCLUSIONS

Performance measures for DAE in the UK meet the ESGE quality benchmarks, with high diagnostic and therapeutic yields, and a low incidence of major adverse events. However, there is room for improvement in optimizing sedation practices, standardizing the depth of insertion documentation, and adopting marking techniques to aid in the follow-up of detected lesions.

Diagnostic conundrum: an elusive bleeding source in patient with recurrent gastrointestinal bleeding

Over a 6-month period, a 69-year-old woman presented with recurrent symptomatic anaemia, melaena and haematochezia. Extensive investigations were carried out, including CT of the abdomen and pelvis, oesophagogastroduodenoscopy, colonoscopy, two capsule endoscopies and two CT angiograms. The lack of active bleeding at the time of both CT angiograms meant a diagnosis was only made following retrospective examination of images by interventional radiology once fresh ampullary bleeding was identified on capsule endoscopy. The unifying diagnosis was haemosuccus pancreaticus given the combination of the left gastric artery pseudoaneurysm, fresh bleeding identified from ampulla and the patient's history of chronic alcohol-related pancreatitis. Subsequent coil embolisation was performed to an optimal result with no recurrence of symptoms to date.

Are accelerated infliximab infusions safe in patients with inflammatory bowel disease?

BACKGROUND

Infliximab is a monoclonal antibody used in the treatment of inflammatory bowel disease (IBD). The manufacturer-recommended administration is over 2 hours followed by 2 hours of patient observation. The data relating to adverse outcomes in patients receiving accelerated infusions for IBD are limited.

METHODS

Our unit utilizes an accelerated protocol for infliximab infusion in selected patients with IBD (those with no adverse reaction in their first four standard infusions). Our aim was to assess if the accelerated infusion protocol (infusion over 1 hour or 30 minutes with 1 hour or no monitoring according to protocol) was associated with any increase in adverse outcomes. Data were collected retrospectively on protocol used and adverse outcomes for all infliximab infusions between October 2005 and June 2008.

RESULTS

Out of 69 patients, 27 received the accelerated protocol (130 infusions). All patients received a total of 306 infusions on the standard protocol. No adverse reactions were reported in the accelerated protocol patients. In patients on the standard protocol, 16 adverse reactions were observed: seven were acute (occurring during infusion); nine were delayed (occurring within 1-7 days following infusion). No patient required intramuscular adrenaline or hospitalization.

CONCLUSIONS

Our findings suggest that an accelerated protocol for infliximab infusion is well tolerated in selected patients. The monitoring period following infusion may not be necessary, as all acute reactions occurred within an hour of initiating infusion and did not warrant hospitalization. The accelerated infusion may allow more efficient utilization of hospital resources and reduce patient inconvenience.

CURRENT CLINICAL APPLICATIONS OF ENDOSCOPIC ULTRASOUND

Endoscopic ultrasound (EUS) has been developed since the early 1980s. Its clinical role in the diagnosis of gastrointestinal wall lesions and staging of gastrointestinal and lung cancer has evolved over the last two decades. Initially, it was either used as an imaging tool for gastrointestinal wall lesions or for staging of gastrointestinal tumours. However, in combination with fine-needle aspiration under real-time scanning, EUS is now being used in tissue sampling for diagnosis. In addition, EUS may be used therapeutically in coeliac plexus neurolysis or pseudocyst drainage. This review concentrates on the current applications of EUS.

Plasma concentrations of glucagon-like peptide-2 in adult patients with treated and untreated coeliac disease

BACKGROUND

Coeliac disease is a common chronic inflammatory enteropathy characterized by villous atrophy and crypt hyperplasia in the small intestine. The mechanism of the intestinal damage in coeliac disease remains unclear. Glucagon-like peptide (GLP)-2 is an enterotrophic peptide that causes crypt hyperplasia and intestinal cell proliferation. We postulate that GLP-2 may be involved in the mucosal changes found in coeliac disease.

OBJECTIVES

To study plasma concentrations of GLP-2 in untreated patients with coeliac disease and determine the response to a gluten-free diet (GFD).

METHODS

A 440 kcal gluten-free test meal was given to seven controls and 12 coeliac patients at three time intervals: (1) before commencing a GFD; (2) 3 months after a GFD; and (3) 9 months after a GFD. Serial blood sampling was performed over a 2-h period. Each sample was analysed using radioimmunoassay for GLP-2, GLP-1, N-terminal glucagon (N-glucagon) and C-terminal glucagon (C-glucagon).

RESULTS

Untreated coeliac patients had significantly higher basal and peak GLP-2 and N-glucagon plasma concentrations compared with controls. After 3 months on a GFD, there was a significant decrease in basal GLP-2 plasma concentrations. There was no significant difference between GLP-1 or C-glucagon in untreated coeliac patients compared with controls.

CONCLUSION

This is the first reported study of GLP-2 in coeliac disease. After a GFD there is recovery of the intestine and a reduction in the GLP-2 trophic response. Our findings support the theory that GLP-2 may be part of the mucosal healing and maintenance mechanisms in coeliac disease.

The effect of erythromycin on video capsule endoscopy intestinal-transit time

BACKGROUND

Video capsule endoscopy (VCE) will fail to reach the cecum in 20% of patients within the 8-hour battery life. The use of prokinetics to improve VCE completion rates to the cecum remains unclear. The objective of this study was to determine whether erythromycin increases the completion rate of VCE to the cecum without adversely affecting image quality.

METHODS

This was a prospective, randomized, single-blinded control trial at St. Vincent's Hospital, Melbourne, Australia. A total of 86 consecutive patients referred for VCE were considered for entry; 45 patients met the entry criteria. These 45 patients were prospectively randomized to no erythromycin (controls, n = 23) or 250 mg erythromycin (n = 22). Two gastroenterologists, who were unaware of which group the patients were randomized into, reported all VCEs. The number of VCEs that reached the cecum within the 8-hour study period, gastric emptying time (GET), and small-bowel transit time (SBTT) were calculated for each group.

RESULTS

There was no significant difference in the number of VCEs that reached the cecum (32% failed to reach the cecum in the erythromycin group compared with 22% in the control group), GET, or SBTT between the two groups. Image quality was not adversely affected by the use of erythromycin. The dose and the preparation of erythromycin used in this study may have possibly had an effect on GET and SBTT.

CONCLUSIONS

The use of erythromycin did not significantly increase the likelihood of the capsule reaching the cecum or affect the degree of visible peristalsis or the interpretation of capsule findings.

Gallstone disease: Symptoms, diagnosis and endoscopic management of common bile duct stones

Bile duct stones (BDS) are often suspected on history and clinical examination alone but symptoms may be variable ranging from asymptomatic to complications such as biliary colic, pancreatitis, jaundice or cholangitis. The majority of BDS can be diagnosed by transabdominal ultrasound, computed tomography, endoscopic ultrasound or magnetic resonance cholangiography prior to endoscopic or laparoscopic removal. Approximately 90% of BDS can be removed following endoscopic retrograde cholangiography (ERC)+sphincterotomy. Most of the remaining stones can be removed using mechanical lithotripsy. Patients with uncorrected coagulopathies may be treated with ERC+pneumatic dilatation of the sphincter of Oddi. Shockwave lithotripsy (intraductal and extracorporeal) and laser lithotripsy have also been used to fragment large bile duct stones prior to endoscopic removal. The role of medical therapy in treatment of BDS is currently uncertain. This review focuses on the clinical presentation, investigation and current management of BDS.

Natural history of asymptomatic bile duct stones at time of cholecystectomy

OBJECTIVES

There is little data on the natural history of asymptomatic bile duct stones and hence there is uncertainty on the management of asymptomatic bile duct stones discovered incidentally at the time of laparoscopic cholecystectomy. We retrospectively reviewed a group of patients who had previously underwent laparoscopic cholecystectomy, but who did not have a pre-operative suspicion of intra-ductal stones, to determine if any biliary complications had subsequently developed. A group of patients who had no pre-operative suspicion of intra-ductal stones, but routinely underwent intraoperative cholangiogram (IOC) at time of cholecystectomy, served as the control group.

METHODS

A telephone questionnaire was completed by each patient's family practitioner in 59 of 79 (75%) patients who underwent laparoscopic cholecystectomy. In the remaining 20 patients additional information was obtained from hospital records and from the central services agency (CSA). These patients had no pre-operative suspicion of bile duct stones and therefore did not undergo an IOC or ERCP. The control group (73 patients) had no pre-operative suspicion of bile duct stones but had a routine IOC performed to define the biliary anatomy.

RESULTS

59 patients were followed up for an average of 57 months (range 30-78 months) after laparoscopic cholecystectomy. None of these patients developed pancreatitis, jaundice, deranged liver function tests (LFT's), or required ERCP or other biliary intervention. In the additional 20 patients where no information was available from the family practitioner, 11 patients had follow up appointments with no documentation of biliary complications or abnormal LFT's. 19 of 20 patients were traceable through the CSA and were all alive. Only 1 patient was untraceable and therefore unknown if biliary complications had developed. In the control group, 4 of 73 (6%) patients had intraductal stones detected and extracted. Thus the prevalence of asymptomatic bile duct stones during the time of cholecystectomy in our population was 6%.

CONCLUSIONS

Asymptomatic bile duct stones discovered at the time of cholecystectomy do not appear to cause any biliary complications over a 5-year follow up. Incidental bile duct stones found in patients undergoing laparoscopic cholecystectomy may not need to be removed.

Prospective study of the clinical impact of EUS

BACKGROUND

Studies on the clinical impact of EUS are lacking. The aim of this study was to examine the impact of EUS on the management plans by referring doctors and patient outcomes.

METHODS

Consecutive patients undergoing EUS between August 2002 and June 2004 were prospectively studied. Referring doctors were given a pre-EUS questionnaire that asked about provisional diagnosis and management plan. A post-EUS questionnaire was sent 6 weeks after the procedure.

RESULTS

A total of 330 patients were examined, and completed questionnaires were received in 70%. EUS-guided FNA was performed in 69 (30%) patients. EUS resulted in a change in diagnosis and management in 26% and 48% of cases, respectively. Thirty-nine of the latter patients (33%) avoided unnecessary surgery. In 50% of cases, additional investigations were avoided. Doctors reported EUS as very or moderately useful in 210 patients (91%). Doctors of 223 patients (97%) reported that they would use EUS again.

CONCLUSIONS

The use of EUS had a significant clinical impact on patients. EUS resulted in a change of diagnosis in a fourth of patients and a change in management in half of patients studied.

Cognitive behavior therapy in the treatment of multiple personality

The case of Audrey H. represents the first successful cognitive behavioral treatment of a multiple personality reported in the literature. In this article the construct of multiple personality is briefly reviewed from various theoretical perspectives. The therapeutic approach chosen involved first the analysis of the emotions and behaviors of each subpersonality and then the process of integrating each alternate by cognitively developing in Audrey the realization that her various alternates all were facets of the same individual. Various specific behavioral procedures were employed, all within a generally orchestrated program of cognitive restructuring. Five years after the completion of therapy, this patient was experiencing no dissociation whatsoever and only moderate levels of anxiety.

Contributions to behavioral treatment from studies on programmed access to alcohol

Major developments in research involving the alcohol-alcoholic interaction are presented against a backdrop of the traditional perspective of alcoholism. Studies explaining the effects of alcohol, factors influencing drinking patterns, the significance of alcohol for the alcoholic, expectations regarding alcohol use and its affective and social consequences, the parameters of alcohol use, the question of control of alcoholism, and a number of treatment related issues are reviewed. It is concluded that much of this research is provocative and may recommend a reassessment of current thinking about the nature of alcohol abuse and dependence. Such a reassessment, however, is seen to be difficult to make, for the task likely will require a paradigmatic shift.

Behavioral treatment methods for alcoholism

This chapter offers a review of the behavioral methodology directed to the treatment of alcoholism. Beginning with an outline of the theoretical bases of behavior therapy and assessment, a review with some historical perspective is undertaken of the chemical, electrical, and covert aversion treatments of alcoholism. Thereafter, the procedures of the social skills-training strategies (including marital skills and assertiveness training) are presented, followed by a discussion of the relaxation and desensitization techniques. The operant methodologies are illustrated by contingency contracting and the community-reinforcement approaches. Within the broad-spectrum procedures, a description of self-control training and an example of a broad-spectrum treatment study are offered. It is noted that although the merits of these various techniques are becoming widely recognized in the alcoholism treatment literature, the behavior therapeutic approaches to alcoholism have yet to receive widespread public acceptance. It is anticipated that future studies of treatment effectiveness will contribute to an increasing appreciation of the advantages of behavioral therapies to the management of alcohol abuse and dependence.

Abstinence and controlled drinking in the treatment of problem drinkers

Issues regarding abstinence and restricted drinking as treatment goals are discussed. It is argued that therapies oriented to both controlled drinking and abstinence are needed. Problems with differential assignment of patients to treatment modalities are considered, and tentative guidelines for the selection of treatment goals are proposed.

Fallibility of urine drug screens in monitoring methadone programs

Urine specimens containing five different drugs, each at three levels of concentration with zero to five drugs in a specimen, were sent to two "approved" laboratories. In only 46.9% and 13.8%, respectively, were all drugs present correctly identified and no false-positive results reported. With some allowances, the results improved to 53.8% and 49.4%. If these tests are to be continued then (1) the fallibility of these tests should be known by all treatment personnel, (2) laboratories should be licensed rather than merely approved, and (3) maintenance of the license should be made contingent on passing "blind" proficiency tests.

Attitudes toward alcohol as predictors of self-estimated alcohol consumption in college students

The purpose of the present investigation was to examine the relationship between attitudes toward alcohol use and self-estimated drinking behavior. The results indicated that attitudes can reliably predict variations in self-reported drinking behavior. The implication of these findings for treatment and future research is discussed.

Gallstone disease: Symptoms, diagnosis and endoscopic management of common bile duct stones

Bile duct stones (BDS) are often suspected on history and clinical examination alone but symptoms may be variable ranging from asymptomatic to complications such as biliary colic, pancreatitis, jaundice or cholangitis. The majority of BDS can be diagnosed by transabdominal ultrasound, computed tomography, endoscopic ultrasound or magnetic resonance cholangiography prior to endoscopic or laparoscopic removal. Approximately 90% of BDS can be removed following endoscopic retrograde cholangiography (ERC)+sphincterotomy. Most of the remaining stones can be removed using mechanical lithotripsy. Patients with uncorrected coagulopathies may be treated with ERC+pneumatic dilatation of the sphincter of Oddi. Shockwave lithotripsy (intraductal and extracorporeal) and laser lithotripsy have also been used to fragment large bile duct stones prior to endoscopic removal. The role of medical therapy in treatment of BDS is currently uncertain. This review focuses on the clinical presentation, investigation and current management of BDS.